Request Demo
Last update 12 Apr 2025
Anti-MUC1 CAR-T cell/PD-1 knockout engineered T cell therapy (Guangzhou Anjie Biomedical Technology)
Last update 12 Apr 2025
Overview
Basic Info
Drug Type CAR-T |
Synonyms AntiMUC1 CAR T cells and PD1 knockout engineered T cells, AntiMUC1 CART cells combined with PD1 knockout engineered T cells |
Target |
Action inhibitors |
Mechanism MUC1 inhibitors(Mucin-1 inhibitors), Gene transference, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with Anti-MUC1 CAR-T cell/PD-1 knockout engineered T cell therapy (Guangzhou Anjie Biomedical Technology)ChiCTR1900025088
Early dose pilot study for MUC1 positive advanced breast cancer treated with pd-1 knockout MUC1 target chimeric antigen receptor T cells (AJMUC1)
NCT05812326
Exploratory Clinical Study of PD-1 Knockout Targeting MUC1 CAR-T Cells (AJMUC1) in the Treatment of MUC1-positive Advanced Breast Cancer
NCT03525782
A Clinical Study of Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for Patients With Advanced Non-small Cell Lung Cancer
100 Clinical Results associated with Anti-MUC1 CAR-T cell/PD-1 knockout engineered T cell therapy (Guangzhou Anjie Biomedical Technology)
Login to view more data
100 Translational Medicine associated with Anti-MUC1 CAR-T cell/PD-1 knockout engineered T cell therapy (Guangzhou Anjie Biomedical Technology)
Login to view more data
100 Patents (Medical) associated with Anti-MUC1 CAR-T cell/PD-1 knockout engineered T cell therapy (Guangzhou Anjie Biomedical Technology)
Login to view more data
100 Deals associated with Anti-MUC1 CAR-T cell/PD-1 knockout engineered T cell therapy (Guangzhou Anjie Biomedical Technology)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced breast cancer | Phase 2 | China | 17 May 2019 | |
| Esophageal Carcinoma | Phase 2 | China | 15 Sep 2018 | |
| Non-Small Cell Lung Cancer | Phase 2 | China | 20 Jan 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free